Piramal Enterprises demerger: Wrong math or a mispriced opportunity?
The demerger of Piramal Enterprises (PEL) was a long awaited one in the market. With sizable businesses in both financial services and pharmaceuticals, the demerger aroused significant interest among investors from a value creation point of view. But the combined value of financial services and pharmaceutical businesses took considerable hit post demerger and gave a […]
Piramal Enterprises demerger: Wrong math or a mispriced opportunity? Read More »